NeuroMetrix Announces Quell Now Available on through Amazon Launchpad

WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #chronicpain–NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that the
Company’s Quell® Wearable Pain Relief device is now available
on Amazon Launchpad.

Amazon Launchpad is a program that makes it easy for startups to launch,
market, and distribute their products to hundreds of millions of Amazon
customers across the globe. Amazon Launchpad has worked with over 100
leading venture capital firms, startup accelerators, and crowd-funding
platforms to help more than 1,000 startups launch products in the U.S.,
U.K., China, Germany, France, and Canada. To shop the Amazon Launchpad
store, visit

“We are excited that Quell is now being sold on through the
Amazon Launchpad program,” said Frank McGillin, Senior Vice President
and Chief Commercial Officer of NeuroMetrix. “This allows for additional
educational content for consumers, and now that Quell is shipped and
sold by Amazon, customers can take advantage of the fast, free shipping
benefits of Amazon Prime.”

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can start, stop, and adjust therapy discreetly
via the optional Quell Relief app. Quell also offers advanced sleep
tracking that provides feedback on eight dimensions of sleep including
sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the
2016 SXSW (South by Southwest) Innovation Award for Best Wearable
Technology. Quell is available at select healthcare professionals and
retailers. Visit for
more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer